Apimeds Pharmaceuticals US Inc (APUS) has a current Price-to-Book (P/B) ratio of 3.53. Compared to its 3-year average P/B ratio of -0.15, the current P/B ratio is approximately -2415.50% higher. Relative to its 5-year average P/B ratio of -0.15, the current P/B ratio is about -2415.50% higher. Apimeds Pharmaceuticals US Inc (APUS) has a Forward Free Cash Flow (FCF) yield of approximately -18.21%. Compared to its 3-year average FCF yield of -13.61%, the current FCF yield is approximately 33.75% lower. Relative to its 5-year average FCF yield of -13.61%, the current FCF yield is about 33.75% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for APUS competitors is 0.25, providing a benchmark for relative valuation. Apimeds Pharmaceuticals US Inc Corp (APUS.A) exhibits a P/S ratio of --, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of APUS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of APUS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is APUS currently overvalued or undervalued?

What is Apimeds Pharmaceuticals US Inc (APUS) fair value?

APUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Apimeds Pharmaceuticals US Inc (APUS) is between to according to relative valuation method.

How does APUS's valuation metrics compare to the industry average?

The average P/S ratio for APUS's competitors is 0.25, providing a benchmark for relative valuation. Apimeds Pharmaceuticals US Inc Corp (APUS) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Apimeds Pharmaceuticals US Inc (APUS) as of Mar 04 2026?

As of Mar 04 2026, Apimeds Pharmaceuticals US Inc (APUS) has a P/B ratio of 3.53. This indicates that the market values APUS at 3.53 times its book value.

What is the current FCF Yield for Apimeds Pharmaceuticals US Inc (APUS) as of Mar 04 2026?

As of Mar 04 2026, Apimeds Pharmaceuticals US Inc (APUS) has a FCF Yield of -18.21%. This means that for every dollar of Apimeds Pharmaceuticals US Inc's market capitalization, the company generates -18.21 cents in free cash flow.

What is the current Forward P/E ratio for Apimeds Pharmaceuticals US Inc (APUS) as of Mar 04 2026?

As of Mar 04 2026, Apimeds Pharmaceuticals US Inc (APUS) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Apimeds Pharmaceuticals US Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Apimeds Pharmaceuticals US Inc (APUS) as of Mar 04 2026?

As of Mar 04 2026, Apimeds Pharmaceuticals US Inc (APUS) has a Forward P/S ratio of 0.00. This means the market is valuing APUS at $0.00 for every dollar of expected revenue over the next 12 months.

APUS Valuation